Corcept Therapeutics Incorporated (CORT) — Cash Flow Quality Index
Corcept Therapeutics Incorporated (CORT) has a Cash Flow Quality Index of 0.39x as of December 2025. Operating cash flow of $38.45 Million is below net income of $98.17 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore CORT cash flow conversion to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Corcept Therapeutics Incorporated Cash Flow Quality Index (2016–2025)
Historical Cash Flow Quality Index for Corcept Therapeutics Incorporated across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check cash flow reinvestment rate of Corcept Therapeutics Incorporated to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Corcept Therapeutics Incorporated (2016–2025)
Year-by-year earnings quality comparison for Corcept Therapeutics Incorporated. For live market cap and the full company financial profile, see Corcept Therapeutics Incorporated stock valuation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 1.45x | $142.00 Million | $98.17 Million | ▲ +3.1% |
| 2024 | 1.40x | $198.07 Million | $141.21 Million | ▲ +17.2% |
| 2023 | 1.20x | $127.04 Million | $106.14 Million | ▲ +0.9% |
| 2022 | 1.19x | $120.32 Million | $101.42 Million | ▼ -20.5% |
| 2021 | 1.49x | $167.89 Million | $112.51 Million | ▲ +4.1% |
| 2020 | 1.43x | $151.97 Million | $106.01 Million | ▼ -0.8% |
| 2019 | 1.45x | $136.12 Million | $94.18 Million | ▼ -5.8% |
| 2018 | 1.53x | $115.67 Million | $75.41 Million | ▲ +225.0% |
| 2017 | 0.47x | $60.94 Million | $129.12 Million | ▼ -79.1% |
| 2016 | 2.26x | $18.39 Million | $8.14 Million | — |